Home > Boards > US OTC > Biotechs >

Aeolus Pharmaceuticals (AOLS)

Add AOLS Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Sheep
Search This Board: 
Last Post: 1/11/2018 3:58:04 PM - Followers: 19 - Board type: Free - Posts Today: 0



Our strategy is to use non-dilutive capital wherever possible to develop our exciting platform of broad-spectrum catalytic antioxidant compounds in important unmet indications of national strategic importance.  We plan to continue to leverage that capital, like the investment made by U.S. government agencies, such as NIH-NIAID and NIH CounterACT, in AEOL 10150 as a medical countermeasure, to concurrently develop these promising compounds for use in significant unmet medical indications, like oncology. We are currently doing this with AEOL 10150, where we are leveraging the potential substantial government investment in research and development of AEOL 10150 as a medical countermeasure to develop the compound in oncology indications, where it would be used in combination with radiation therapy

Business Overview

 We are developing a platform of a new class of broad-spectrum catalytic antioxidant compounds based on technology discovered at Duke University and National Jewish Health. These compounds, known as metalloporphyrins, scavenge reactive oxygen species ("ROS") at the cellular level, mimicking the effect of the body's own natural antioxidant enzyme superoxide dismutase ("SOD").  While the benefits of antioxidants in reducing oxidative stress are well-known, research with our compounds indicates that metalloporphyrins can be used to affect signaling via ROS at the cellular level.  In addition, there is evidence that high-levels of ROS can affect gene expression and this may be modulated through the use of metalloporphyrins. We believe this could have a profound beneficial impact on people who have been exposed, or are about to be exposed, to high-doses of radiation.

Our lead compound, AEOL 10150, is a metalloporphyrin specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure.  We are leveraging the significant investment made by U.S. government agencies to develop this promising compound for use in oncology indications, where it would be used in combination with radiation therapy, and is currently in development for use as both a therapeutic and prophylactic drug. 

AEOL 10150 has previously been tested in two Phase I clinical trials with no serious adverse events reported.  Data have already been published showing that AEOL 10150 does not interfere with the therapeutic benefit of radiation therapy in prostate and lung cancer preclinical studies.  Early next year we expect to release data showing the drug's impact, if any, when used in combination with radiation and/or chemotherapy.  In mid-2011 we expect to begin Phase I/II studies in non-small cell lung cancer ("NSCLC").

AEOL 10150 is also being developed as a medical countermeasure against the pulmonary sub-syndrome of acute radiation syndrome ("Pulmonary Acute Radiation Syndrome" or "Lung-ARS") as well as the gastrointestinal sub-syndrome of acute radiation syndrome ("GI-ARS"), both caused by exposure to high levels of radiation due to a radiological or nuclear event.  It is also being developed for use as a countermeasure for exposure to chemical vesicants such as chlorine gas and sulfur mustard gas.  AEOL 10150 has already performed well in animal efficacy and safety studies in each of these potential indications.  A significant portion of the funding for the medical countermeasure development programs to date has come from various government entities.    Although our management expects this funding to continue, there is no guarantee that it will do so.  We have submitted proposals to the Biomedical Advanced Research and Development Authority ("BARDA") to develop AEOL 10150 as countermeasures for both Lung-ARS and cholorine gas exposure.  We are awaiting a final decision from BARDA on the contract.  If the contract from BARDA is awarded, it is expected that it will fund all of the costs to bring AEOL 10150 to FDA approval for that indication.

We have two programs underway for the development of our second drug candidate, AEOL 11207, for the treatment of epilepsy and Parkinson's disease.   These programs are being funded, in part, by private foundations and government grants.


 PDF Presentation Feb 2011:



Share Structure:

60,470,718 outstanding shares as of  MAY 10,2011
200,000,000 shares authorized

~ 6 - 9 Million shares in the Float
as of Jan 26, 2011



Point of Contact:

CFO: Russell Skibsted

Public Company, Headquarters Location
26361 Crown Valley Pkwy., Ste. 150, Mission Viejo, CA 92691-7324, United States
(949)481-9825, (949)481-9829 fax

AOLS (Daily)

AOLS (Weekly)


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AOLS News: Termination of Registration of a Class of Security Under Section 12(g) (15-12g) 12/22/2017 04:53:22 PM
AOLS News: Quarterly Report (10-q) 08/14/2017 05:09:19 PM
#636   Just doing a little research and found this Sheep 01/11/18 03:58:04 PM
#635   A little resistance here the big move will Profit 01/10/18 06:10:23 PM
#634   Some nice buying going on around .07. jimbob4stocks 01/10/18 11:15:39 AM
#633   Exactly why I'm here. Its more of an Profit 01/09/18 06:12:55 PM
#632   I have thought the same thing. For some Sheep 01/09/18 10:25:17 AM
#631   Aeolus Pharmaceutica (AOLS) mick 01/08/18 11:37:42 PM
#630   I can see this boards going to have Profit 01/08/18 07:52:33 PM
#629   Lookin Solid Profit 01/08/18 07:42:18 PM
#628   Happy to see the new year and the GetSeriousOK 01/08/18 07:06:17 PM
#627   I would love for the company to say Sheep 01/08/18 12:48:54 PM
#626   Nice to see AOLS back up jimbob4stocks 01/08/18 11:21:43 AM
#625   very good run/ thank you $AOLS mick 01/08/18 09:00:47 AM
#624   Sitting on this waiting for the move. $$$AOLS$$$ Profit 01/05/18 07:23:14 PM
#623   THANK YOU $AOLS mick 01/05/18 09:12:44 AM
#622   Tax loss selling is done, looks like a Profit 01/02/18 09:11:56 PM
#621   I wouldn't worry about the e-mail. I've jimbob4stocks 01/02/18 03:01:48 PM
#620   I hope that is the case. I did Sheep 01/02/18 01:35:34 PM
#619   Seems like tax loss sellers and weak hands jimbob4stocks 01/02/18 10:14:38 AM
#618   I think they will. Hoping for something jimbob4stocks 12/29/17 03:20:24 PM
#617   I really think the company should have honestly Sheep 12/29/17 11:25:03 AM
#616   Nice! jimbob4stocks 12/28/17 12:50:22 PM
#615   Picked some up today! investorsa 12/28/17 12:49:47 PM
#614   As of July 1, they had roughly $750K jimbob4stocks 12/28/17 09:49:09 AM
#613   Anyone know how long the company has before Zlinger 12/27/17 11:02:37 PM
#612   Waiting for news of a path forward not Profit 12/27/17 10:02:13 PM
#611   I saw it. Still holding my shares. jimbob4stocks 12/27/17 09:05:05 PM
#610   No one commenting on the deregistration statement? Thoughts? highstreettrader 12/27/17 08:58:27 PM
#609   Haha amen to that jimbob4stocks 12/18/17 07:51:49 PM
#608   heh, I like these tax-selling dips but I'll GetSeriousOK 12/18/17 04:50:13 PM
#607   Same here. AOLS has been around since jimbob4stocks 12/18/17 10:04:41 AM
#606   That "other company" is GSK. Aeolus, in their GetSeriousOK 12/16/17 10:19:28 AM
#605   Has the potential to explode! Will sit on Profit 12/15/17 04:55:24 PM
#604   I'm holding and waiting too. I agree this Sheep 12/15/17 02:21:51 PM
#603   This is one you tuck away. jimbob4stocks 12/15/17 01:12:00 PM
#602   From what turned to expectation of a banner Falco 12/15/17 05:33:00 AM
#601   Great time to average down jimbob4stocks 12/13/17 10:12:02 AM
#600   Couldn't agree more. Upside is too high jimbob4stocks 12/05/17 10:33:57 AM
#599   I'm thinking (OK, hoping) that BARDA will correct GetSeriousOK 12/04/17 07:11:06 PM
#598   Nice find! No 8k filed by Aeolus -- GetSeriousOK 12/04/17 07:02:15 PM
#597   Got my eye on it has potential and Profit 12/01/17 11:00:29 PM
#596   Ready for a update :) MADDSTACKER 12/01/17 01:56:37 PM
#595   Got my bid set in case someone feels Profit 12/01/17 06:51:20 AM
#594 mick 12/01/17 05:52:53 AM
#593   Been a long term investor in AOLS too Falco 11/30/17 04:54:16 AM
#592   Nearly six months since the FDA fast track Zlinger 11/28/17 11:02:11 PM
#591   Aeolus sold their 35% stake in Gencaro to jimbob4stocks 11/28/17 11:12:56 AM
#590   Someone got a nice buy this morning. Can't Sheep 11/27/17 03:52:21 PM
#589   Sun bitch talk about crumbs some one dropped Profit 11/22/17 10:13:36 AM
#588   Agreed tucked away .... for news day !! MADDSTACKER 11/22/17 09:43:53 AM
#587   Agreed someone needed MADDSTACKER 11/22/17 09:43:23 AM